Evidence map›Paper›PMID 39424713›Full record

ArticleDermatology and therapy2024

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.

Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jonathan I SilverbergGeorge Washington University School of Medicine, Washington, DC, USA. jonathanisilverberg@gmail.com.ORCID http://orcid.org/0000-0003-3686-7805
Andreas WollenbergDepartment of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.ORCID http://orcid.org/0000-0003-0177-8722
Linda Stein GoldHenry Ford Health System, Detroit, MI, USA.ORCID http://orcid.org/0000-0002-2758-1605
James Del RossoJDR Dermatology Research, Las Vegas, NV, USA.ORCID http://orcid.org/0000-0003-4215-7340
Gil YosipovitchMiller School of Medicine, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0001-6303-1822
Peter LioNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-7600-0152
Jose-Manuel CarrascosaHospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4266-0771
Gaia GalloEli Lilly and Company, Indianapolis, IN, USA.
Yuxin DingEli Lilly and Company, Indianapolis, IN, USA.
Zhenhui XuCIMS Global LLC, Somerset, NJ, USA.ORCID http://orcid.org/0000-0003-0821-1008
Marta CasillasEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-6339-5279
Evangeline PierceEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-8287-2835
Helena AgellAlmirall S.A., Barcelona, Spain.
Sonja StänderCenter for Chronic Pruritus and Department of Dermatology, University Hospital Münster, Münster, Germany.ORCID http://orcid.org/0000-0003-3612-7786

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39424713
PMCPMC11557798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.